NCT00170001View on ClinicalTrials.gov

Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy

NACompletedINTERVENTIONAL

Enrollment

500

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions

Gastroesophageal Reflux

Interventions

DRUG

Nexium

40 mg bid dosing

DRUG

Sugar Pill

40 mg BID

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Mayo Clinic

OTHER